Synthesis and evaluation of iodinated TZTP-derivatives as potential radioligands for imaging of muscarinic M2 receptors with SPET

Nuclear Medicine and Biology

Volumn 31, Issue 1, 2004, Pages 111-123

  Knol, Remco J J ^a   Doornbos, Tamme ^b   Van Den Bos, Jan C ^b   De Bruin, Kora ^a   Pfaffendorf, Martin ^c   Aanhaanen, Wim ^a   Janssen, Anton G M ^b   Vekemans, Joseph A J M ^d   Van Eck Smit, Berthe L F ^a   Booij, Jan ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Amersham Health   (Netherlands)

^c UNIVERSITY OF BONN   (Germany)

^d EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

Author keywords

Alzheimer's disease; Cholinergic system; Muscarinic M2 receptor subtype; SPET; TZTP

Indexed keywords

5 [4 [(3 IODO 2 PROPENYL)THIO] 1,2,5 THIADIAZOL 3 YL] 1,2,3,6 TETRAHYDRO 1 METHYLPYRIDINE; 5 [4 [(4 IODO 3 BUTENYL)THIO] 1,2,5 THIADIAZOL 3 YL] 1,2,3,6 TETRAHYDRO 1 METHYLPYRIDINE; 5 [4 [(5 IODO 4 PENTENYL)THIO] 1,2,5 THIADIAZOL 3 YL] 1,2,3,6 TETRAHYDRO 1 METHYLPYRIDINE I 123; IODINE DERIVATIVE; KETANSERIN; MUSCARINIC M2 RECEPTOR; NICOTINE; PYRIDINE DERIVATIVE; RADIOLIGAND; SCOPOLAMINE; THIADIAZOLE DERIVATIVE; TRACER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; DRUG UPTAKE; IMAGING; IN VITRO STUDY; IN VIVO STUDY; IODINATION; MALE; NONHUMAN; PHOTON EMISSION TOMOGRAPHY; RAT; RECEPTOR AFFINITY; SINGLE PHOTON EMISSION TOMOGRAPHY;

EID: 1642451801     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(03)00095-7     Document Type: Article

References (42)

1. Baskin D.S., Browning J.L., Pirozzolo F.J., Korporaal S., Baskin J.A., Appel S.H. Brain choline acetyltransferase and mental function in Alzheimer disease. Arch Neurol. 56:1999;1121-1123.
2. 18F]FP-TZTP control and competition studies . J Cereb Blood Flow Metab. 18:1998;1130-1142.
3. Coyle J.T., Price D.L., DeLong M.R. Alzheimer's disease a disorder of cortical cholinergic innervation . Science. 219:1983;1184-1190.
4. Davis K.L., Mohs R.C., Marin D., Purohit D.P., Perl D.P., Lantz M., Austin G., Haroutunian V. Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA. 281:1999;1401-1406.
5. DeKosky S.T., Scheff S.W. Synapse loss in frontal cortex biopsies in Alzheimer's disease correlation with cognitive severity . Ann Neurol. 27:1990;457-464.
6. Eckelman W.C. Radiolabeled muscarinic radioligands for in vivo studies. Nucl Med Biol. 28:2001;485-491.
7. 3 receptors in guinea-pig ileum and atria in vitro. Br J Pharmacol. 109:1993;946-952.
8. Farber N.E., Harkin C.P., Niedfeldt J., Hudetz A.G., Kampine J.P., Schmeling W.T. Region-specific and agent-specific dilation of intracerebral microvessels by volatile anesthetics in rat brain slices. Anesthesiology. 87:1997;1191-1198.
9. Felder C.C., Bymaster F.P., Ward J., DeLapp N. Therapeutic opportunities for muscarinic receptors in the central nervous system. J Med Chem. 43:2000;4333-4353.
10. Flynn D.D., Ferrari-DiLeo G., Levey A.I., Mash D.C. Differential alterations in muscarinic receptor subtypes in Alzheimer's disease implications for cholinergic-based therapies . Life Sci. 56:1995;869-876.
11. Fryer A.D., el Fakahany E.E. Identification of three muscarinic receptor subtypes in rat lung using binding studies with selective antagonists. Life Sci. 47:1990;611-618.
12. Geula C. Abnormalities of neural circuitry in Alzheimer's disease hippocampus and cortical cholinergic innervation . Neurology. 51:1998;S18-S29.
13. Giacobini E. Invited review Cholinesterase inhibitors for Alzheimer's disease therapy: from tacrine to future applications . Neurochem Int. 32:1998;413-419.
14. Goodman M.M., Kung M.P., Kabalka G.W., Kung H.F., Switzer R. Synthesis and characterization of radioiodinated N-(3-iodopropen-1-yl)- 2 beta-carbomethoxy-3 beta-(4-chlorophenyl)tropanes potential dopamine reuptake site imaging agents . J Med Chem. 37:1994;1535-1542.
15. Hansen T.D., Warner D.S., Todd M.M., Vust L.J., Trawick D.C. Distribution of cerebral blood flow during halothane versus isoflurane anesthesia in rats. Anesthesiology. 69:1988;332-337.
16. 18F]FP-TZTP, is greatly decreased in M2 receptor knockout mice but not in M1, M3 and M4 receptor knockout mice. Neuropharmacology. 44:2003;653-661.
17. Jung M.E., Light L.A. Preparation of iodoallylic alcohols via hydrostannylation spectroscopic proof of structures . Tetrahedron Lett. 23:1982;3851-3854.
18. Kiesewetter D.O., Carson R.E., Jagoda E.M., Herscovitch P., Eckelman W.C. In vivo muscarinic binding of 3-(alkylthio)-3-thiadiazolyl tetrahydropyridines. Synapse. 31:1999;29-40.
19. Kiesewetter D.O., Carson R.E., Jagoda E.M., Herscovitch P., Eckelman W.C. Using single photon emission tomography (SPECT) and positron emission tomography (PET) to trace the distribution of muscarinic acetylcholine receptor (MACHR) binding radioligands. Life Sci. 64:1999;511-518.
20. 18F-labeled muscarinic agonist with M2 selectivity. J Med Chem. 38:1995;5-8.
21. Krall W.J., Sramek J.J., Cutler N.R. Cholinesterase inhibitors a therapeutic strategy for Alzheimer disease . Ann Pharmacother. 33:1999;441-450.
22. Levey A.I. Muscarinic acetylcholine receptor expression in memory circuits implications for treatment of Alzheimer disease . Proc Natl Acad Sci USA. 93:1996;13541-13546.
23. Li M., Yasuda R.P., Wall S.J., Wellstein A., Wolfe B.B. Distribution of m2 muscarinic receptors in rat brain using antisera selective for m2 receptors. Mol Pharmacol. 40:1991;28-35.
24. Mash D.C., Flynn D.D., Potter L.T. Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation. Science. 228:1985;1115-1117.
25. Mash D.C., Potter L.T. Autoradiographic localization of M1 and M2 muscarine receptors in the rat brain. Neuroscience. 19:1986;551-564.
26. Neary D., Snowden J.S., Mann D.M., Bowen D.M., Sims N.R., Northen B., Yates P.O., Davison A.N. Alzheimer's disease a correlative study . J Neurol Neurosurg Psychiatry. 49:1986;229-237.
27. Nordberg A. Nicotinic receptor abnormalities of Alzheimer's disease therapeutic implications . Biol Psychiatry. 49:2001;200-210.
28. Perry E.K., Morris C.M., Court J.A., Cheng A., Fairbairn A.F., McKeith I.G., Irving D., Brown A., Perry R.H. Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease possible index of early neuropathology . Neuroscience. 64:1995;385-395.
29. Podruchny T.A., Connolly C., Bokde A., Herscovitch P., Eckelman W.C., Kiesewetter D.O., Sunderland T., Carson R.E., Cohen R.M. In vivo muscarinic 2 receptor imaging in cognitively normal young and older volunteers. Synapse. 48:2003;39-44.
30. Quirion R., Martel J.C., Robitaille Y., Etienne P., Wood P., Nair N.P., Gauthier S. Neurotransmitter and receptor deficits in senile dementia of the Alzheimer type. Can J Neurol Sci. 13:1986;503-510.
31. Reinikainen K.J., Riekkinen P.J., Halonen T., Laakso M. Decreased muscarinic receptor binding in cerebral cortex and hippocampus in Alzheimer's disease. Life Sci. 41:1987;453-461.
32. Rijks L.J., Booij J., Doornbos T., Boer G.J., Ronken E., de Bruin K., Vermeulen R.J., Janssen A.G., Van Royen E.A. In vitro and in vivo characterization of newly developed iodinated 1-[2- [bis(4-fluorophenyl)methoxy] ethyl]piperazine derivatives in rats limited value as dopamine transporter SPECT ligands . Synapse. 23:1996;201-207.
33. Rodriguez-Puertas R., Pascual J., Vilaro T., Pazos A. Autoradiographic distribution of M1, M2, M3, and M4 muscarinic receptor subtypes in Alzheimer's disease. Synapse. 26:1997;341-350.
34. 2 muscarinic acetylcholine receptor protein in cholinergic and non-cholinergic terminals in rat hippocampus. Neurosci Lett. 284:2000;182-186.
35. Rouse S.T., Thomas T.M., Levey A.I. Muscarinic acetylcholine receptor subtype, m2 diverse functional implications of differential synaptic localization . Life Sci. 60:1997;1031-1038.
36. Sauerberg P., Olesen P.H., Nielsen S., Treppendahl S., Sheardown M.J., Honore T., Mitch C.H., Ward J.S., Pike A.J., Bymaster F.P. Novel functional M1 selective muscarinic agonists. Synthesis and structure-activity relationships of 3-(1,2,5-thiadiazolyl)-1,2,5,6- tetrahydro-1-methylpyridines. J Med Chem. 35:1992;2274-2283.
37. Sauerberg P., Olesen P.H., Sheardown M.J., Rimvall K., Thogersen H., Shannon H.E., Sawyer B.D., Ward J.S., Bymaster F.P., DeLapp N.W., Calligaro D.O., Swedberg M.D. Conformationally constrained analogues of the muscarinic agonist 3-(4-(methylthio)-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1- methylpyridine. Synthesis, receptor affinity, and antinociceptive activity. J Med Chem. 41:1998;109-116.
38. 3H]epibatidine binding in relation to vesicular acetylcholine transport sites in the temporal cortex in Alzheimer's disease. Neuroscience. 94:1999;685-696.
39. Terry R.D., Masliah E., Salmon D.P., Butters N., DeTeresa R., Hill R., Hansen L.A., Katzman R. Physical basis of cognitive alterations in Alzheimer's disease synapse loss is the major correlate of cognitive impairment . Ann Neurol. 30:1991;572-580.
40. Tiraboschi P., Hansen L.A., Alford M., Masliah E., Thal L.J., Corey-Bloom J. The decline in synapses and cholinergic activity is asynchronous in Alzheimer's disease. Neurology. 55:2000;1278-1283.
41. Whitehouse P.J., Price D.L., Struble R.G., Clark A.W., Coyle J.T., Delon M.R. Alzheimer's disease and senile dementia loss of neurons in the basal forebrain . Science. 215:1982;1237-1239.
42. Zimmerman J.J., Feldman S. Physical-chemical properties and biological activity. Foye W.O. Principles of medicinal chemistry. 1989;7-37 Lea & Febiger, Philadelphia.